InMode Ltd. (NASDAQ:INMD) Holdings Decreased by North Growth Management Ltd.

North Growth Management Ltd. lessened its stake in InMode Ltd. (NASDAQ:INMD) by 1.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 584,000 shares of the healthcare company’s stock after selling 11,000 shares during the period. InMode accounts for 1.9% of North Growth Management Ltd.’s portfolio, making the stock its 22nd biggest holding. North Growth Management Ltd. owned about 0.70% of InMode worth $9,760,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Inspire Advisors LLC increased its position in shares of InMode by 45.5% during the 3rd quarter. Inspire Advisors LLC now owns 31,192 shares of the healthcare company’s stock valued at $529,000 after purchasing an additional 9,759 shares during the period. Nisa Investment Advisors LLC raised its position in InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after acquiring an additional 2,694 shares in the last quarter. GW Henssler & Associates Ltd. acquired a new stake in InMode in the 3rd quarter valued at about $177,000. EMC Capital Management boosted its position in shares of InMode by 219.4% during the 3rd quarter. EMC Capital Management now owns 13,319 shares of the healthcare company’s stock valued at $226,000 after purchasing an additional 9,149 shares in the last quarter. Finally, Harvey Capital Management Inc. boosted its position in shares of InMode by 57.1% during the 3rd quarter. Harvey Capital Management Inc. now owns 50,790 shares of the healthcare company’s stock valued at $861,000 after purchasing an additional 18,450 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

Analyst Ratings Changes

INMD has been the subject of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Barclays increased their price objective on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, BTIG Research initiated coverage on InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.00.

InMode Trading Down 1.2 %

Shares of INMD stock opened at $18.04 on Friday. The stock’s fifty day simple moving average is $17.36 and its 200-day simple moving average is $17.21. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of 7.68 and a beta of 2.13. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.